<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491633</url>
  </required_header>
  <id_info>
    <org_study_id>11-142</org_study_id>
    <nct_id>NCT01491633</nct_id>
  </id_info>
  <brief_title>Dasatinib in Advanced Squamous Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Dasatinib in Advanced (Stage IIIB/IV) Squamous Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dasatinib is a drug that has been shown to stop some cancer cells from growing. This drug has
      been used in treatment for other types of cancer and information from other research studies
      suggests that dasatinib may help to stop squamous cell lung cancer from growing, especially
      in individuals whose tumor has a mutation in the DDR2 gene.

      Advanced squamous cell lung cancer (SqCC) carries a poor prognosis and new therapeutic
      targets are needed. Several studies have examined dasatinib in NSCLC; these report
      significant toxicities, but also responses in patients found to harbor mutations in DDR2 or
      BRAF.

      An open-label phase II trial with dasatinib was carried out to determine the response rates
      in patients with SqCC who had previously failed standard chemotherapy and to correlate
      responses with patient genotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dasatinib will be taken orally, daily in cycles of 28 days.

      On the first day of study treatment and at 2 weeks, 4 weeks and then every 4 weeks subjects
      will have the following:

        -  Medical history and clinical exam

        -  Safety blood tests

        -  Measurement of Performance Status

        -  Review of pill log

        -  CT scans will be done every 8 weeks.

      In this research study, the investigators are looking at how well dasatinib works in treating
      squamous cell lung cancer.

      Dasatinib administered at 140mg per day for the treatment of advanced SqCC of the lung is
      associated with excess adverse events, similar to other studies, so is not recommended in
      unselected patients. Further work to identify patients likely to benefit from dasatinib and
      in managing dasatinib-related toxicities is needed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety issues/concerns per DF/HCC PI
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the overall response rate of patients with squamous cell carcinoma of the lung treated with dasatinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Types and Frequency of DDR2 Mutations</measure>
    <time_frame>2 years</time_frame>
    <description>Determine frequency of DDR2 mutations in study patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Establish the overall survival of patients with SCC treated with dasatinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Define the toxicities of dasatinib when administered to the patient population. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 will be utilized for adverse event reporting.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Squamous Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 140 mg by mouth each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>140 mg orally, daily in 28 day cycles</description>
    <arm_group_label>Dasatinib</arm_group_label>
    <other_name>BMS-354825</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage III/B or IV squamous NSCLC

          -  Measurable disease

          -  Previously offered all standard chemotherapy regimens for advanced squamous cell lung
             cancer

          -  ECOG performance status of 0 or 1

          -  Estimated life expectancy greater than 12 weeks

          -  Normal organ and marrow function

          -  Confirmed availability of archival pathology samples

          -  Agrees to discontinue St. Johns Wort

          -  Able to take medications by mouth

          -  Willing and able to use acceptable method of birth control for the entire study period
             and for at least 4 weeks after the last dose of study drug

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Chemotherapy or radiotherapy within 4 weeks prior to entering study

          -  Receiving any other investigational agents

          -  Known untreated or progressive brain metastases

          -  History of prior treatment with or allergic reactions attributed to compounds of
             similar chemical or biologic composition to dasatinib, nilotinib or imatinib

          -  Taking medications known to be potent CYP3A4 inhibitors

          -  Currently taking H2 inhibitors or proton pump inhibitors

          -  Currently taking drugs or have taken drugs in the past 7 days that are generally
             accepted to have a risk of causing Torsades de Pointes

          -  HIV positive

          -  Clinically uncontrolled hypertension (blood pressure &gt; 160/110)

          -  Previous or concurrent malignancy except adequately treated basal or squamous cell
             skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively,
             and without evidence of recurrence for at least 5 years

          -  Active and uncontrolled clinically significant infection

          -  Chronic gastrointestinal disease

          -  Acquired or congenital bleeding disorder or clinically significant gastrointestinal
             bleeding within 3 months

          -  Supplemental oxygen required for current malignancy

          -  Evidence of symptomatic pleural effusions unless undergoing a therapeutic
             thoracentesis as part of non-study care

          -  Individuals who are prisoners or who are compulsory detained for medical or
             psychiatric reasons

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Hypokalemia or hypomagnesemia that cannot be corrected prior to dasatinib
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov;8(11):1434-7. doi: 10.1097/JTO.0b013e3182a47162.</citation>
    <PMID>24128713</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <results_first_submitted>May 14, 2014</results_first_submitted>
  <results_first_submitted_qc>June 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2014</results_first_posted>
  <last_update_submitted>June 14, 2014</last_update_submitted>
  <last_update_submitted_qc>June 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Bruce Johnson, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Stage IIIB</keyword>
  <keyword>Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib</title>
          <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib</title>
          <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="55" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Determine the overall response rate of patients with squamous cell carcinoma of the lung treated with dasatinib</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Determine the overall response rate of patients with squamous cell carcinoma of the lung treated with dasatinib</description>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No subjects were evaluable for response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Types and Frequency of DDR2 Mutations</title>
        <description>Determine frequency of DDR2 mutations in study patients</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Types and Frequency of DDR2 Mutations</title>
          <description>Determine frequency of DDR2 mutations in study patients</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Establish the overall survival of patients with SCC treated with dasatinib</description>
        <time_frame>2 years</time_frame>
        <population>One subject who was alive at the end of the study was censored from the survival analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Establish the overall survival of patients with SCC treated with dasatinib</description>
          <population>One subject who was alive at the end of the study was censored from the survival analysis</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicities</title>
        <description>Define the toxicities of dasatinib when administered to the patient population. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 will be utilized for adverse event reporting.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicities</title>
          <description>Define the toxicities of dasatinib when administered to the patient population. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 will be utilized for adverse event reporting.</description>
          <units>grade 3 toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Time on Study</title>
        <description>Number of days participant remained on study</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Time on Study</title>
          <description>Number of days participant remained on study</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib</title>
          <description>Dasatinib 140 mg by mouth each day
Dasatinib: 140 mg orally, daily in 28 day cycles</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated LFTs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the toxicity of the study agent no subjects were evaluable for response</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Peter Hammerman</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-3000</phone>
      <email>phammerman@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

